Fig. 5
Performance evaluation of recombinant antigens in the newly developed anti-HCV immunoassay. Patients’ sera were assayed using the optimized EIA format, and S/Co values were calculated. All viremic sera (n = 190) besides 326 (85.12%) and 359 (93.75%) responder sera tested against both the denatured A and soluble antigens B showed OD450 values > S/Co threshold (2.75), while 14.88% (n = 57) and 6.25% (n = 25) of the Ab+-non-viremic sera of DAA-responders and/or immunocompromised patients showed OD450 values < S/Co threshold (2.75), respectively. C, D: The concordance of S/Co values of patients’ sera assayed against denatured and soluble antigens, respectively, where 80.04% (n = 357) and 89.01% (n = 397) of tested samples were concordant with the findings of the viral RNA quantification results, whereas 19.95% (n = 89) and 10.98% (n = 49) were anti-HCV discrepant